Mechanisms of sex steroids: Future developments

Maturitas

Volumn 47, Issue 4, 2004, Pages 285-291

  Kuhl, Herbert ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Hormone therapy; Mechanism; Sex steroids

Indexed keywords

CENTCHROMAN; CONJUGATED ESTROGEN; CYPROTERONE ACETATE; DESOGESTREL; DEXAMETHASONE; DIENOGEST; DIETHYLSTILBESTROL DERIVATIVE; DROLOXIFENE; ESTRADIOL; ESTROGEN DERIVATIVE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETONOGESTREL; FLAVONOID; FULVESTRANT; GESTAGEN; GESTODENE; GLUCOCORTICOID; IDOXIFENE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; NOMEGESTROL ACETATE; NORETHISTERONE; PHYTOESTROGEN; PROGESTERONE; PROGESTERONE RECEPTOR MODULATOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE;

ATHEROGENESIS; ATHEROSCLEROSIS; BINDING AFFINITY; BREAST CANCER; BREAST EPITHELIUM; CANCER RISK; CELL MIGRATION; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DRUG ACTIVITY; DRUG BINDING; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; ESTROGEN DEFICIENCY; EXPERIMENTAL MODEL; HEART INFARCTION; HORMONAL CONTRACEPTION; HORMONE SUBSTITUTION; HUMAN; IN VIVO STUDY; MAMMARY GLAND; MUSCLE CELL; NONHUMAN; ORAL CONTRACEPTION; POSTMENOPAUSE; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT OUTCOME; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 1942504137     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2003.11.010     Document Type: Conference Paper

References (35)

1. McKenna N.J., Lanz R.B., O'Malley B.W. Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev. 20:1999;321-344.
2. Kuiper G.G.J.M., Carlsson B., Grandien K.et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β Endocrinology. 139:1997;863-870.
3. Enmark E., Pelto-Huikko M., Grandien K.et al. Human estrogen receptor β-gene structure, chromosomal localization, and expression pattern. J. Clin. Endocrinol. Metab. 82:1997;4258-4265.
4. Gebhart J.B., Rickard D.J., Barrett T.J., Lesnick T.G., Webb M.J., Podratz K.C.et al. Expression of estrogen receptor isoforms α and β messenger RNA in vaginal tissue of premenopausal and postmenopausal women. Am. J. Obstet. Gynecol. 185:2001;1325-1331.
5. Oettel M., Elger W., Gräser T., Holz C., Lähteenmäki P., Patchev What is past is prologue: estrogen/progestin replacement tomorrow. Gynecol. Endocrinol. 15(Suppl. 4):2001;68-90.
6. Chwalisz K., Brenner R.M., Fuhrmann U.U., Hess-Stumpp H., Elger W. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids. 65:2000;741-751.
7. Kloosterboer H.J., Deckers G.H., Schoonen W.G.E.J., Hanssen R.G.J.M., Rose U.M., Verbost P.M.et al. Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids. 65:2000;733-740.
8. Arnett-Mansfield R.L., deFazio A., Wain G.V., Jaworski R.C., Byth K., Mote P.A.et al. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res. 61:2001;4576-4582.
9. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B.et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 280:1998;605-613.
10. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33.
11. Scarabin PY, Oger E, Plu-Bureau G, on behalf of the Estrogen and ThromboEmbolism Risk (ESTHER) Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-32.
12. Cline J.M., Soderqvist G., von Schoultz E., Skoog L., von Schoulktz B. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgous macaques. Am. J. Obstet. Gynecol. 174:1996;93-100.
13. Hofseth L.J., Raafat A.M., Osuch J.R., Pathak D.R., Slomski C.A., Haslam S.Z. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J. Clin. Endocrinol. Metab. 84:1999;4559-4565.
14. Ménard S., Casalini P., Agresti R., Pilotti S., Balsari A. Proliferation of breast carcinoma during menstrual phases. Lancet. 352:1998;148-149.
15. Adams M.R., Kaplan J.R., Manuck S.B., Koritnik D.R., Parks J.S., Wolfe M.S.et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovarectomized monkeys. Arteriosclerosis. 10:1990;1051-1057.
16. Hodis H.N., Mack W.J., Lobo R.A., Skhoupe D., Sevanian A., Mahrer P.R.et al. Estrogen in the prevention of atherosclerosis. Ann. Interrn. Med. 135:2001;939-953.
17. Wagner J.D., Clarkson T.B., St. Clair R.W., Schwenke D.C., Shively C.A., Adams M.R. Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J. Clin. Invest. 88:1991;1995-2002.
18. Adams M.R., Register T.C., Golden D.L., Wagner J.D., Williams J.K. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17:1997;217-221.
19. Clarkson T.B., Anthony M.S., Wagner J.D. A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys. J. Clin. Endocrinol. Metab. 86:2001;5396-53404.
20. Williams J.K., Honoré E.K., Washburn S.A., Clarkson T.B. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J. Am. Coll. Cardiol. 24:1994;1757-1761.
21. Miyagawa K., Rösch J., Stanczyk F., Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat. Med. 3:1997;324-327.
22. Williams J.K., Cline J.M., Honoré E.K., Delansome R., Paris J. Coadministration of nomegestrol acetate does not diminish the beneficial effects of estradiol on coronary artery dilator responses in nonhuman primates (Macaca fascicularis). Am. J. Obstet. Gynecol. 179:1998;1288-1294.
23. Collins P., Rosano G.M., Sarrel P.M., Ulrich L., Adamopoulos S., Beale C.M.et al. 17β-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation. 92:1995;24-30.
24. Reis S.E., Gloth S.T., Blumenthal R.S., Resar J.R., Zacur H.A., Gerstenblith G.et al. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation. 89:1994;52-60.
25. Adams M.R., Clarkson T.B., Shively C.A., Parks J.S., Kaplan J.R. Oral contraceptives, lipoproteins, and atherosclerosis. Am. J. Obstet. Gynecol. 163:1990;1388-1393.
26. Brosens I.A., Pijnenborg R. Comparative study of the estrogenic effect of ethinylestranol and mestranol on the endometrium. Contraception. 14:1976;679-685.
27. Petitti D.B., Sidney S., Quesenberry C.P. Oral contraceptive useand myocardial infarction. Contraception. 57:1998;143-155.
28. Gerstman B.B., Piper J.M., Tomita D.K., Ferguson W.J., Stadel B.V., Lundin E.E. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am. J. Epidemiol. 133:1991;32-37.
29. Kemmeren J.M., Algra A., Grobbee D.E. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. Br. Med. J. 323:2001;131-134.
30. Vasilakis-Scaramozza C., Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet. 358:2001;1427-1429.
31. Parkin L., Skegg D.C., Wilson M.et al. Oral contraceptives and fatal pulmonary embolism. Lancet. 355:2000;2133-2134.
32. Rosing J., Tans G., Nicolaes G.A.F., Thomassen M.C.L.G.D., van Oerle R., van der Ploeg P.M.E.N.et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br. J. Haematol. 97:1997;233-238.
33. Kluft C., de Maat M.P.M., Heinemann L.A.J., Spannagl M., Schramm W. Importance of levonorgestrel dose in oral contraceptives for effects on coagulation. Lancet. 354:1999;832-833.
34. Yang Z., Arnet U., Bauer E., von Segesser L., Siebenmann R., Turina M.et al. Thrombin-induced endothelium-dependent inhibition and direct activation of platelet-vessel wall interaction. Circulation. 89:1994;2266-2272.
35. Herkert O., Kuhl H., Sandow J., Busse R., Schini-Kerth V.B. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression. Role of the glucocorticoid receptor. Circulation. 104:2001;2826-2831.